Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias

被引:19
作者
Albers, Max B. [1 ,2 ,3 ]
Almquist, Martin [1 ,2 ]
Bergenfelz, Anders [1 ,2 ]
Nordenstrom, Erik [1 ,2 ]
机构
[1] Lund Univ, Skane Univ Hosp, Dept Surg, Lund, Sweden
[2] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden
[3] Philipps Univ Marburg, Dept Visceral Thorac & Vasc Surg, Marburg, Germany
关键词
Neuroendocrine neoplasia; Perioperative complications; Surgery; Gastro-entero-pancreatic system; Small intestine; Pancreas; ENETS CONSENSUS GUIDELINES; POSTOPERATIVE COMPLICATIONS; TUMORS; MANAGEMENT; UPDATE; RESECTION; CLASSIFICATION; MORTALITY; PROPOSAL; OUTCOMES;
D O I
10.1007/s00423-020-01869-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose Surgery is recommended for most patients with gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NENs). Rates of complications and perioperative mortality have been reported in few mostly retrospective single-center series, but there has been no detailed analysis on risk factors for perioperative complications and mortality to date. Methods Data of patients with GEP-NENs operated between January 2015 and September 2018 were retrieved from EUROCRINE (c), a European online endocrine surgical quality registry, and analyzed regarding rate and risk factors of surgical complications. Risk factors were assessed by logistic regression. Results Some 376 patients (211 female, 167 male; age median 63, range 15-89 years) were included. Most NENs were located in the small intestine (SI) (n = 132) or pancreas (n = 111), the rest in the stomach (n = 34), duodenum (n = 30), appendix (n = 30), colon, and rectum (n = 22), or with unknown primary (n = 15). Of the tumors, 320 (85.1%) were well or moderately differentiated, and 147 (39.1%) of the patients had distant metastases at the time of operation. Severe complications (Dindo-Clavien >= 3) occurred in 56 (14.9%) patients, and 4 (1.1%) patients died perioperatively. Severe complications were more frequent in surgery for duodenopancreatic NENs (n = 31; 22.0%) compared with SI-NENs (n = 15; 11.4%) (p = 0.014), in patients with lymph node metastases operated with curative aim of surgery (n = 24; 21.4%) versus non-metastasized tumors or palliative surgery (n = 32; 12.1%) (p = 0.020), and in functioning tumors (n = 20; 23.0%) versus non-functioning tumors (n = 30; 13.5%) (p = 0.042). Complication rates were not significantly associated with tumor stage or grade. Conclusions Severe complications are frequent in GEP-NEN surgery. Besides duodenopancreatic tumor location, curative resection of nodal metastases and functioning tumors are risk factors for complications.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 50 条
[31]   An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm [J].
Liu, Hua ;
Xie, Rongli ;
Zhao, Zhifeng ;
Xu, Dan ;
Yang, Kaige ;
Ding, Min ;
Tan, Dan ;
Liao, Wenqiang ;
Han, Xujie ;
Zhang, Jun ;
Shen, Dongjie ;
Yuan, Jianmin ;
Xu, Zhiwei ;
Fei, Jian .
MEDICINE, 2020, 99 (33) :E21682
[32]   Current Status of Interventional Radiology in the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs) [J].
Orgera, Gianluigi ;
Krokidis, Miltiadis ;
Cappucci, Matteo ;
Gourtsoyianni, Sofia ;
Tipaldi, Marcello Andrea ;
Hatzidakis, Adam ;
Rebonato, Alberto ;
Rossi, Michele .
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2015, 38 (01) :13-24
[33]   Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours [J].
Gurusamy, Kurinchi Selvan ;
Pamecha, Viniyendra ;
Sharma, Dinesh ;
Davidson, Brian R. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01)
[34]   Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort [J].
Walter, T. ;
Tougeron, D. ;
Baudin, E. ;
Le Malicot, K. ;
Lecomte, T. ;
Malka, D. ;
Hentic, O. ;
Manfredi, S. ;
Bonnet, I. ;
Guimbaud, R. ;
Coriat, R. ;
Lepere, C. ;
Desauw, C. ;
Thirot-Bidault, A. ;
Dahan, L. ;
Roquin, G. ;
Aparicio, T. ;
Legoux, J-L. ;
Lombard-Bohas, C. ;
Scoazec, J-Y. ;
Lepage, C. ;
Cadiot, G. .
EUROPEAN JOURNAL OF CANCER, 2017, 79 :158-165
[35]   Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Oberg, K. ;
Knigge, U. ;
Kwekkeboom, D. ;
Perren, A. .
ANNALS OF ONCOLOGY, 2012, 23 :124-130
[36]   Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro-entero-pancreatic neuroendocrine neoplasms: A scoping review [J].
Kashyap, Raghava ;
Raja, Senthil ;
Adusumilli, Ajay ;
Gopireddy, Murali Mohan Reddy ;
Loveday, Benjamin P. T. ;
Alipour, Ramin ;
Kong, Grace .
JOURNAL OF NEUROENDOCRINOLOGY, 2025, 37 (03)
[37]   Role of [18 F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors [J].
Magi, L. ;
Prosperi, D. ;
Lamberti, G. ;
Marasco, M. ;
Ambrosini, V ;
Rinzivillo, M. ;
Campana, D. ;
Annibale, B. ;
Signore, A. ;
Panzuto, F. .
JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 :152-152
[38]   The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro-Entero-Pancreatic (GEP-NEN) System [J].
Gebauer, Niklas ;
Ziehm, Maria ;
Gebauer, Judith ;
Riecke, Armin ;
Meyhoefer, Sebastian ;
Kulemann, Birte ;
von Bubnoff, Nikolas ;
Steinestel, Konrad ;
Bauer, Arthur ;
Witte, Hanno M. .
CANCERS, 2022, 14 (21)
[39]   Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) - Current literature review of diagnostics and therapy. What has changed in the management? [J].
Jurkiewicz, Krzysztof ;
Miciak, Michas ;
Kaliszewski, Krzysztof .
POLISH JOURNAL OF SURGERY, 2024, 96 (04) :58-66
[40]   Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study [J].
Masui, Toshihiko ;
Ito, Tetsuhide ;
Komoto, Izumi ;
Uemoto, Shinji .
BMC CANCER, 2020, 20 (01)